AI Article Synopsis
- Massachusetts initiated standing orders for naloxone to increase accessibility and reduce opioid overdose deaths, conducting a trial to evaluate access differences between users of illicit opioids and bystanders.
- The study involved 200 pharmacies, with each undergoing two purchase attempts: one by a person who uses illicit opioids and another by a bystander, assessing the success of naloxone purchases.
- Results showed a high success rate (81%) for naloxone purchases, but with significant disparities in counseling received, particularly for users of illicit opioids, highlighting the need for improved access in independent pharmacies.
Article Abstract
Objectives: Massachusetts was among the first states to allow standing orders to facilitate pharmacy-based naloxone purchases and reduce opioid overdose deaths. We conducted a unique purchase trial to establish a valid measure of standing order naloxone in Massachusetts, using purchasers from 2 high priority populations to determine whether naloxone is less accessible to those who use illicit opioids than other potential purchasers.
Design: Purchase trial.
Setting And Participants: The study used a stratified random sample of 200 chain and independent retail pharmacies across Massachusetts. Each pharmacy underwent 2 purchase attempts-1 by a person who used illicit opioids (PWUIO) and 1 by a potential bystander who did not use illicit opioids but had a relationship with someone at risk of opioid overdose.
Outcome Measure: Successful or unsuccessful naloxone purchase attempt.
Results: Overall, 322 of 397 purchase attempts (81%) were successful, with no statistically significant difference between PWUIO and bystanders (P = 0.221). Most purchases (93%) resulted in the acquisition of single-step nasal naloxone (Narcan; median cost $133.38). Forty percent of the purchases included state-mandated verbal counseling, and PWUIO were significantly less likely to receive counseling than bystanders (30% vs. 51%, P < 0.001). Common reasons for failed purchase were not stocking naloxone (47%), price > $150 (25%), and requiring a prescription (15%). Chain pharmacies were significantly more likely to sell naloxone than independent pharmacies (86% vs. 53%, P < 0.001).
Conclusion: We documented high levels of naloxone access for both PWUIO and bystanders, suggesting Massachusetts could serve as a model for states seeking to improve pharmacy-based naloxone access. Additional implementation efforts should focus on expanding availability at independent pharmacies and supporting pharmacies in proactively offering naloxone to PWUIO and other high-risk individuals.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655699 | PMC |
| http://dx.doi.org/10.1016/j.japh.2020.05.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A cross-sectional survey exploring organizational readiness to implement community pharmacy-based opioid counseling and naloxone services in rural versus urban settings in Alabama.
Explor Res Clin Soc Pharm
December 2024
Auburn University Harrison College of Pharmacy, Department of Health Outcomes Research and Policy, 4306 Walker Building, Auburn, AL 36849, USA.
Background: Rural US regions experience lower naloxone dispensing rates compared to urban counterparts, particularly in Alabama. In light of this, strategies to enhance opioid counseling and naloxone services (OCN) in rural community pharmacies are critical. However, organizational readiness to implement OCN in rural versus urban contexts where resource networks may differ is not well understood.
View Article and Find Full Text PDFDevelopment of pharmacy-based best practices to support safer use and management of prescription opioids based on an e-Delphi methodology.
Res Social Adm Pharm
December 2024
Monash Addiction Research Centre, Monash University, 47-49 Moorooduc Hwy, Frankston, 3199, Victoria, Australia.
Background: Opioid utilization and related harm have increased in recent decades, notably in Australia, the United States, Canada, and some European countries. For people who are prescribed opioids, pharmacies offer an accessible, regular point-of-contact, providing a unique opportunity to address opioid prescription drugs risks.
Objective: This project aimed to develop consensus-based, best practice statements for improving the safer use of prescription opioids through community pharmacy settings.
Naloxone Availability and Cost After Transition to an Over-the-Counter Product.
JAMA Health Forum
July 2024
UNC Eshelman School of Pharmacy, Asheville, North Carolina.
Importance: The US Food and Drug Administration approved Narcan, a nasal spray formulation of naloxone, for sale as an over-the-counter (OTC) medication in March 2023. The purpose of OTC approval was to improve naloxone accessibility to reduce opioid overdoses; however, research has not yet evaluated whether naloxone's availability and cost changed since this policy was implemented.
Objective: To evaluate whether the accessibility and cost of naloxone at North Carolina community pharmacies changed after OTC naloxone became available and whether cost and availability varied by pharmacy type and urbanicity.
Community pharmacists' attitudes toward and practice of pharmacy-based harm reduction services in Pittsburgh, PA: a descriptive survey.
Harm Reduct J
July 2024
Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA, USA.
Background: In Pittsburgh, PA, legal changes in recent decades have set the stage for an expanded role for community pharmacists to provide harm reduction services, including distributing naloxone and non-prescription syringes (NPS). In the wake of the syndemics of the COVID-19 pandemic and worsening overdose deaths from synthetic opioids, we examine knowledge, attitudes, and practices of harm reduction services among community pharmacists in Pittsburgh and identify potential barriers of expanded pharmacy-based harm reduction services.
Methods: We provided flyers to 83 community pharmacies within a 5-mile radius of the University of Pittsburgh Medical Center to recruit practicing community pharmacists to participate in an anonymous electronic survey.
Revisiting the opioid and naloxone education (ONE) program: Program evaluation using the RE-AIM model four years later.
Res Social Adm Pharm
July 2024
ONE Program Resident Pharmacist, North Dakota State University, Fargo, ND, USA.
Objective: The Opioid and Naloxone Education (ONE) Program focuses on community pharmacy-based patient screening and interventions to improve population health with regard to opioid use. The purpose of this paper is to reevaluate the ONE Program performance using the RE-AIM model, in comparison to the review performed in 2019.
Methods: The program performance of the ONE Program was evaluated from January 1, 2021 to December 31, 2022 was evaluated using the five domains of the RE-AIM model.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!